Farzad Nazem Buys 45,000 Shares of NAUT
Farzad Nazem recently purchased 45,000 shares of NAUT.
Key Points
- Farzad Nazem acquired 45,000 shares of NAUT on June 18, 2026, as part of an insider buy.
- Shares of NAUT traded near $2.31 on Tuesday, with institutional interest from firms like Vanguard Capital Management.
- Analysts from Guggenheim maintained a 'buy' rating with a $4.00 target, while Goldman Sachs rated it 'sell' at $1.75.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Farzad Nazem, an insider at NAUT, recently purchased 45,000 shares of the company on June 18, 2026. This transaction was not part of a planned trading program.
Other Institutional Activity in NAUT
Several institutional investors have also shown interest in NAUT. A16Z Capital Management, L.L.C. holds 17,653,917 shares valued at about $68.5 million. Perceptive Advisors LLC has maintained its position with 12,594,211 shares worth approximately $48.9 million. Vanguard Capital Management LLC opened a new position with 2,545,597 shares valued at nearly $9.9 million. Similarly, Clearstead Advisors, LLC initiated a stake with 2,329,784 shares, valued around $9 million.
Nautilus Biotechnology, Inc. Stock Up 160.8%
Shares of NAUT traded near $2.31 on Tuesday. The stock has seen various institutional activities, suggesting a mix of investor sentiment. The company's market performance is under scrutiny as insiders and institutions adjust their holdings.
$NAUT stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Nautilus Biotechnology, Inc.
On June 18, 2026, several insiders, including Farzad Nazem, each bought 45,000 shares of NAUT. This group included Matthew McIlwain, Matthew Posard, Karen Akinsanya, and Melissa B. Epperly. Additionally, Sujal Patel, the CEO, President, and Secretary, purchased 25,000 shares at an average price of $2.61 on March 4, 2026.
Analysts Set New Price Targets
On February 27, 2026, Guggenheim maintained its 'buy' rating on NAUT with a price target of $4.00. Meanwhile, Goldman Sachs had previously downgraded the stock to a 'sell' with a target of $1.75 on December 8, 2024. Morgan Stanley maintained a 'hold' rating with a $5.00 target back in July 2024.
Bottom Line
Farzad Nazem's recent purchase of 45,000 NAUT shares adds to the insider activity that investors closely watch. With institutional investors like Vanguard Capital Management taking new stakes, NAUT remains a point of interest. Analyst ratings provide a mixed outlook, with significant variations in price targets, reflecting differing views on the company's future performance.
Get Nautilus Biotechnology, Inc. alerts
New 13F filings, insider trades, and analyst moves on $NAUT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.